Alexandra Hughes-Wilson - Jan 25, 2025 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Patient Access and Commercial Planning
Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
Jan 25, 2025
Transactions value $
$0
Form type
4
Date filed
1/28/2025, 04:05 PM
Previous filing
Sep 16, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Share Options (Right to buy) Award $0 +154K $0.00 154K Jan 25, 2025 American Depository Shares 154K $2.91 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter.
F2 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Remarks:

Chief Patient Access and Commercial Planning